Healthcare Costs of Diabetes and Microvascular and Macrovascular Disease in Individuals with Incident Type 2 Diabetes Mellitus: A Ten-Year Longitudinal Study

References

• American Diabetes Association. Standards of Medical Care in Diabetes-2015: Introduction. Diabetes Care. 2015;38(Suppl):S1–S2.
   PubMed Web of Science ®Google Scholar
• Gionfriddo MR, McCoy RG, Lipska KJ. The 2013 American Association of Clinical Endocrinologists’ diabetes mellitus management recommendations: improvements needed. JAMA Intern Med. 2014;174(2):179–180. doi:10.1001/jamainternmed.2013.12971
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes statistics report, 2020. Available from: https://www.cdc.gov/diabetes/data/statistics/statistics-report.html. Accessed April 26, 2020.
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36(4):1033–1046. doi:10.2337/dc12-2625
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–928. doi:10.2337/dci18-0007
   PubMed Web of Science ®Google Scholar
• Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Aff. 2013;6(2):297–303. doi:10.1377/hlthaff.2009.0155
   Web of Science ®Google Scholar
• Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20:6–12. doi:10.1089/pop.2015.0181
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Kahn HS, Bardenheier BH, Li R, Gregg EW. Change in medical spending attributable to diabetes: national data from 1987 to 2011. Diabetes Care. 2016;39(4):1796–1803. doi:10.2337/dc14-1687
   Web of Science ®Google Scholar
• Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term trends in antidiabetes drug usage in the U.S.: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care. 2018;41(1):69–78. doi:10.2337/dc17-1414
   PubMed Web of Science ®Google Scholar
• Bottomley JM. T2ARDIS steering committee. Managing care of type 2 diabetes. Learnings from T2ARDIS. Br J Diabetes Vasc Dis. 2001;1:68–72. doi:10.1177/14746514010010011201
   Google Scholar
• Liebl A, Khunti K, Orozco-Beltran D, Yale JF. Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review. Clin Med Insights Endocrinol Diabetes. 2015;8:13–19.
   PubMedGoogle Scholar
• Beckman JA, Creager MA. Vascular complications of diabetes. Circ Res. 2016;118(11):1771–1785. doi:10.1161/CIRCRESAHA.115.306884
   PubMed Web of Science ®Google Scholar
• Brownrigg JR, Hughes CO, Burleigh D, et al. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. Lancet Diabetes Endocrinol. 2016;4:588–597. doi:10.1016/S2213-8587(16)30057-2
   PubMed Web of Science ®Google Scholar
• Chen HL, Hsu WW, Hsiao FY. Changes in prevalence of diabetic complications and associated healthcare costs during a 10-year follow-up period among a nationwide diabetic cohort. J Diabetes Complications. 2015;29:523–528. doi:10.1016/j.jdiacomp.2015.02.002
   PubMed Web of Science ®Google Scholar
• Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. doi:10.1152/physrev.00045.2011
   PubMed Web of Science ®Google Scholar
• Banerji MA, Dunn JD. Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes. Am Health Drug Benefits. 2013;6:382–392.
   PubMedGoogle Scholar
• Li R, Bilik D, Brown MB, et al. Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care. 2013;19:421–430.
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253–261. doi:10.1016/j.amepre.2013.04.017
   PubMed Web of Science ®Google Scholar
• Weng W, Tian Y, Kong SX, et al. Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. Clin Diabetes Endocrinol. 2020;6(1):5. doi:10.1186/s40842-019-0090-y
   Google Scholar
• Mehta S, Ghosh S, Sander S, Kuti E, Mountford WK. Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease. J Manag Care Spec Pharm. 2018;24(3):280–290. doi:10.18553/jmcp.2018.24.3.280
   PubMed Web of Science ®Google Scholar
• Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care. 2004;27(Suppl 1):S84–S87. doi:10.2337/diacare.27.2007.S84
   PubMed Web of Science ®Google Scholar
• Fong DS, Aiello LP, Ferris FL 3rd, Klein R. Diabetic retinopathy. Diabetes Care. 2004;27(10):2540–2553. doi:10.2337/diacare.27.10.2540
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J, Coupland C. Diabetes treatments and risk of amputation, blindness, severe kidney failure, hyperglycaemia, and hypoglycaemia: open cohort study in primary care. BMJ. 2016;352:i1450. doi:10.1136/bmj.i1450
   PubMed Web of Science ®Google Scholar
• Mohammedi K, Woodward M, Hirakawa Y, et al. Microvascular and macrovascular disease and risk for major peripheral arterial disease in patients with type 2 diabetes. Diabetes Care. 2016;39:1796–1803. doi:10.2337/dc16-0588
   Web of Science ®Google Scholar
• Einarson TR, Acs A, Ludwig C, Panton UH. Economic burden of cardiovascular disease in type 2 diabetes: a systematic review. Value Health. 2018;21(7):881–890. doi:10.1016/j.jval.2017.12.019
   PubMed Web of Science ®Google Scholar
• Ratner RE. The imperative to prevent diabetes. Diabetes Care. 2012;35(12):2417–2418. doi:10.2337/dc12-1997
   Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care. 2016;39(Suppl 1):S4–S5. doi:10.2337/dc16-S003
   PubMedGoogle Scholar
• American Diabetes Association. Standards of medical care in diabetes-2018: introduction. Diabetes Care. 2018;41:S1–S2.
   Web of Science ®Google Scholar
• Rosella LC, Lebenbaum M, Fitzpatrick T, et al. Impact of diabetes on healthcare costs in a population-based cohort: a cost analysis. Diabet Med. 2016;33(3):395–403. doi:10.1111/dme.12858
   PubMed Web of Science ®Google Scholar
• Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes Care. 2014;37(9):2557–2564. doi:10.2337/dc13-2484
   PubMed Web of Science ®Google Scholar
• Roberts S, Barry E, Craig D, Airoldi M, Bevan G, Greenhalgh T. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017;7(11):e017184. doi:10.1136/bmjopen-2017-017184
   PubMed Web of Science ®Google Scholar
• Faxon DP, Creager MA, Smith SC Jr, et al. Atherosclerotic vascular disease conference: executive summary: atherosclerotic vascular disease conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2004;109(21):2595–2604. doi:10.1161/01.CIR.0000128517.52533.DB
   PubMed Web of Science ®Google Scholar
• Long AN, Dagogo-Jack S. Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens. 2011;13:244–251. doi:10.1111/j.1751-7176.2011.00434.x
   PubMed Web of Science ®Google Scholar
• McDermott MM, Criqui MH, Ferrucci L, et al. Obesity, weight change, and functional decline in peripheral arterial disease. J Vasc Surg. 2006;43(6):1198–1204. doi:10.1016/j.jvs.2006.02.036
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care. 1999;22(7):1116–1124. doi:10.2337/diacare.22.7.1116
   Web of Science ®Google Scholar
• Gandra SR, Lawrence LW, Parasuraman BM, Darin RM, Sherman JJ, Wall JL. Total and component health care costs in a non-medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease. J Manag Care Pharm. 2006;12:546–554. doi:10.18553/jmcp.2006.12.7.546
   PubMed Web of Science ®Google Scholar
• Trogdon JG, Hylands T. Nationally representative medical costs of diabetes by time since diagnosis. Diabetes Care. 2008;31(12):2307–2311. doi:10.2337/dc08-1375
   Web of Science ®Google Scholar
• Weng W, Liang Y, Kimball ES, et al. Longitudinal changes in medical services and related costs in a single cohort of patients newly diagnosed with type 2 diabetes, 2006 to 2012. Clin Ther. 2016;38(6):1314–1326. doi:10.1016/j.clinthera.2016.03.032
   PubMed Web of Science ®Google Scholar
• U.S. Bureau of Labor Statistics. Consumer Price Index (CPI) for medical care. 2020. Available from: http://data.bls.gov. Accessed April 14, 2020.
   Google Scholar
• Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–772. doi:10.1161/CIRCULATIONAHA.116.021887
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322. doi:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Mader JK, Lilly LC, Aberer F, et al. Improved glycaemic control and treatment satisfaction with a simple wearable 3-day insulin delivery device among people with type 2 diabetes. Diabet Med. 2018;35(10):1448–1456. doi:10.1111/dme.13708
   PubMed Web of Science ®Google Scholar
• Sutton D, Higdon CD, Nikkel C, Hilsinger KA. Clinical benefits over time associated with use of V-go wearable insulin delivery device in adult patients with diabetes: a retrospective analysis. Adv Ther. 2015;35(5):631–643. doi:10.1007/s12325-018-0703-3
   Web of Science ®Google Scholar
• Shrestha SS, Zhang P, Hora IA, Gregg EW. Trajectory of excess medical expenditures 10 years before and after diabetes diagnosis among U.S. adults aged 25–64 years, 2001–2013. Diabetes Care. 2019;42(1):62–68. doi:10.2337/dc17-2683
   Web of Science ®Google Scholar
• Khan T, Yang J, Wozniak G. Trends in medical expenditures prior to diabetes diagnosis: the early burden of diabetes. Popul Health Manag. 2020. doi:10.1089/pop.2019.0143
   Web of Science ®Google Scholar
• Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics. 2009;27(6):479–490. doi:10.2165/00019053-200927060-00004
   PubMed Web of Science ®Google Scholar
• Papa G, Degano C, Iurato MP, Licciardello C, Maiorana R, Finocchiaro C. Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol. 2013;12(1):20. doi:10.1186/1475-2840-12-20
   Web of Science ®Google Scholar
• Funk MJ, Landi SN. Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr Epidemiol Rep. 2014;1(4):175–185. doi:10.1007/s40471-014-0027-z
   PubMedGoogle Scholar